Results 241 to 250 of about 281,052 (341)

Bavachin enhances paclitaxel sensitivity in ovarian cancer cells through modulation of mitochondrial function and ER stress. [PDF]

Anim Cells Syst (Seoul)
Lee SJ, Kim KK, Lee JY.
europepmc   +1 more source

Paclitaxel: Infusion Duration Effect on Toxicity and Efficacy

, 1995
Cheryl Tate
openalex   +1 more source

The First‐in‐Man Technique of Drug Eluting and Perfusion Therapy for Left Main Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Treating ostial left circumflex artery (LCx) lesions in percutaneous coronary intervention (PCI) for left main disease (LMD) remains a challenge. Despite recent recommendations for the use of drug‐coated balloon (DCB) in this lesion, there are concerns about crossover‐stenting from the left main trunk (LMT) to the left anterior ...
Takayuki Warisawa, Yoshiki Kawai, Takuya Matsumoto, Shingo Sato, Makoto Takeyama, Yuta Nakamura, Susumu Katsushika, Aritomo Katsura, Takahiro Sato, Masashiro Matsushita, Jiro Ando   +10 more
wiley   +1 more source

Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China. [PDF]

Health Econ Rev
Wang L, Chen J, Lin L, Huang X.
europepmc   +1 more source

The Combined Effects of Paclitaxel and Irradiation on the Expression of p21(WAF1), Bax, and Fas.

, 1999
Miho Kawashima, Masatoshi Hasegawa, Kayoko Hayakawa, Michitaka Yamakawa, Norio Mitsuhashi, Hideo Niibe   +5 more
openalex   +2 more sources

Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Various drug‐eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long‐term trials reveal inconsistent results in head‐to‐head comparisons. Aims To conduct a network meta‐analysis of relevant trials to assess the performance of different DES currently used in PCI.
Aman Goyal, Humza Saeed, Sonia Hurjkaliani, Yusra Mashkoor, Abdullah, Gauranga Mahalwar, Ankur Kalra, Grant W. Reed   +7 more
wiley   +1 more source

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study. [PDF]

J Cancer Res Clin Oncol
Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, Park-Simon TW, Häberle L, Uhrig S, Tome O, Spall T, Theuser AK, Ruebner M, Belleville E, Wallwiener D, Brucker SY, Hartkopf AD.   +17 more
europepmc   +1 more source

Comparison between CAP therapy and JP therapy in bone marrow self control case of paclitaxel in ovarian cancer patient.

, 1999
Shunji Matsuki
openalex   +2 more sources

Drug Coated Balloon in Young Patients With ST‐Elevation Myocardial Infarction: A Viable Treatment Option?

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT This clinical case highlights the safety and feasibility of drug coated balloon (DCB) angioplasty in a very young patients presenting with STEMI (ST‐Elevation Myocardial Infarction) to avoid long‐term complications associated with stent implantation, which still amount to 1%−2%.
Davor Vukadinović, Saarraaken Kulenthiran, Felix Mahfoud, Bruno Scheller   +3 more
wiley   +1 more source

Drug Coated Balloons Versus Drug‐Eluting Stents in Patients With De Novo Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with de novo coronary artery disease (CAD), percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation is the gold standard therapy. New evidence is available with drug coated balloons (DCB) angioplasty. The objective of this meta‐analysis was to compare the efficacy and safety of DCB angioplasty
Daniel O'Callaghan, Himanshu Rai, Daniele Giacoppo, J. J. Coughlan, Rory Durand, Valeria Paradies, Róisín Colleran, Gavin J. Blake, Fernando Alfonso, Robert A. Byrne   +9 more
wiley   +1 more source